Migratory and intermittent polyarthritis as an atypical presentation of carnitine palmitoyltransferase II deficiency with positive response to treatment with Interleukin-1 receptor antagonist: a case presentation and case-based review
- PMID: 40580346
- DOI: 10.1007/s00296-025-05917-0
Migratory and intermittent polyarthritis as an atypical presentation of carnitine palmitoyltransferase II deficiency with positive response to treatment with Interleukin-1 receptor antagonist: a case presentation and case-based review
Abstract
Carnitine palmitoyltransferase 2 (CPT2) deficiency is an autosomal recessive disorder affecting fatty-acid metabolism that manifests in three phenotypes: lethal neonatal, infantile and adult. In the adult population, CPT2 deficiency is characterized as the commonest cause of recurrent episodes of rhabdomyolysis. Although inflammatory arthritis has not been previously associated with CPT2 deficiency, existing literature suggests a potential mechanism involving synovial inflammation secondary to the accumulation of fatty acids and acylcarnitine. Attacks are most commonly triggered by infections, strenuous exercise, fasting and consumption of a fat-rich meal. Management in typically conservative, involving dietary modification (high-carbohydrate, low-fat diet) and personalized exercise regimens. The following article describes the case of 43-year old male patient with chronic, intermittent arthritis who was diagnosed with CPT2 deficiency and is currently receiving treatment with interleukin 1 receptor antagonist (IL-1Ra). In addition, a case-based review was conducted to evaluate the possible, underlying mechanisms of inflammatory arthritis in patients with CPT2 deficiency, along with any nuances in the treatment strategy. The presented case, along with the associated case-based literature review, highlight the inflammatory changes taking place in the synovial cells upon accumulation of fatty acids and acylcarnitine molecules that release IL-1β. Finally, the report explores potential future therapeutic strategies.
Keywords: Acylcarnitine; Carnitine palmitoyltransferase 2 (CPT2) deficiency; Fatty acid oxidation; Inflammatory arthritis; Interleukin 1 receptor antagonist (IL-1Ra).
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: No specific funding has been received from any source to carry out the work described above. The authors have declared no competing interest, relevant to the content of this article.
Similar articles
-
Citrullinemia Type I.2004 Jul 7 [updated 2022 Aug 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2004 Jul 7 [updated 2022 Aug 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301631 Free Books & Documents. Review.
-
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180. Health Technol Assess. 2004. PMID: 15130461
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Ornithine Transcarbamylase Deficiency.2013 Aug 29 [updated 2022 May 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2013 Aug 29 [updated 2022 May 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 24006547 Free Books & Documents. Review.
Cited by
-
No role for allopurinol trial as a diagnostic test for gout.Rheumatol Int. 2025 Aug 11;45(9):192. doi: 10.1007/s00296-025-05946-9. Rheumatol Int. 2025. PMID: 40788574 No abstract available.
References
-
- McCormick BJ, Chirila RM (2021) Carnitine palmitoyltransferase– II deficiency: case presentation and review of the literature. Rom J Intern Med 59(4):420–424. https://doi.org/10.2478/rjim-2021-0021 - DOI - PubMed
-
- Choi J, Smith DM, Scafidi S, Riddle RC, Wolfgang M (2024) Carnitine palmitoyltransferase 1 facilitates fatty acid oxidation in a non-cell-autonomous manner. Cell Rep 43:115006. https://doi.org/10.1016/j.celrep.2024.115006 - DOI - PubMed - PMC
-
- Joshi PR, Zierz S (2020) Muscle carnitine palmitoyltransferase II (CPTII) deficiency: a conceptual approach. Molecules 25:1784. https://doi.org/10.3390/molecules25081784 - DOI - PubMed - PMC
-
- Tran TCM, Ta VT, Bui TB, Vu CD, Pham TN (2024) A case study of lethal neonatal CPT II deficiency: novel insights from genetic analysis. MGM reports 41:101170. https://doi.org/10.1016/j.ymgmr.2024.101170 - DOI - PubMed - PMC
-
- Shelihan I, Rossignol E, Decarie JC et al (2022) Infantile onset carnitine palmitoyltransferase 2 deficiency: cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD Reports 63:3–10. https://doi.org/10.1002/jmd2.12243 - DOI - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical